Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib with concurrent radiotherapy and chemotherapy for glioblastoma
ChiCTR2100046932Phase 2Recruiting
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in glioblastoma (GBM), sponsored by Affiliated Hospital of Nantong University. Primary endpoint: Progression-free survival. Started Jun 2021; status: recruiting.
02
Drugs
anlotinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2100046932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046932.